Sarah Sharon Gabriel

Sarah Sharon Gabriel

Auto-generated profile, based on publicly available information

Sarah Sharon Gabriel

Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Immunity
Verified
Journal Article
Closed access
KMKevin Man
Kevin Man
SGSarah S. Gabriel
Sarah S. Gabriel
YLYang Liao
Yang Liao
RGRenee Gloury
Renee Gloury
SPSimon Preston
Simon Preston
AKAxel Kallies
Axel Kallies

20 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
RTRachel Thijssen
Rachel Thijssen
SDSarah T. Diepstraten
Sarah T. Diepstraten
DMDonia Moujalled
Donia Moujalled
ECEdward Chew
Edward Chew
CFChristoffer Flensburg
Christoffer Flensburg
Andrew H WeiAndrew H Wei
Andrew H Wei
Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.

1 November 2019 in Cell Reports
Verified
Journal Article
Open access
MLMichael Low
Michael Low
EBErica J. Brodie
Erica J. Brodie
PFPasquale L. Fedele
Pasquale L. Fedele
YLYang Liao
Yang Liao
GGGeorge Grigoriadis
George Grigoriadis
DTDavid Tarlinton
David Tarlinton
The transcription factor interferon regulatory factor 4 (IRF4) is critical for the development, maintenance, and function of plasma cells. The mechanism by which IRF4 exerts its action in mature plasma cells has been elusive due to the death of all such cells upon IRF4 loss. While we identify apoptosis as a critical pathway for the death of plasma cells caused by IRF4 loss, we also determine that IRF4 did not regulate the intrinsic apoptotic pathway directly. By using an inducible IRF4 deletion system in the presence of the overexpression of anti-apoptotic BCL2, we identify genes whose expression is coordinated by IRF4 and that in turn specify plasma cell identity and mitochondrial homeostasis.

29 July 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SWSharanya K. M. Wijesinghe
Sharanya K. M. Wijesinghe
LRLisa Rausch
Lisa Rausch
SGSarah S. Gabriel
Sarah S. Gabriel
GGGiovanni Galletti
Giovanni Galletti
MLMarco De Luca
Marco De Luca
AKAxel Kallies
Axel Kallies

31 January 2025 in Science Immunology
Verified
Journal Article
Closed access
CGCatarina Gago da Graça
Catarina Gago da Graça
ASAmania A. Sheikh
Amania A. Sheikh
DNDane M. Newman
Dane M. Newman
LWLifen Wen
Lifen Wen
SLSining Li
Sining Li
DUDaniel T. Utzschneider
Daniel T. Utzschneider
Stem-like T cells are attractive immunotherapeutic targets in patients with cancer given their ability to proliferate and differentiate into effector progeny. Thus, identifying T cells with enhanced stemness and understanding their developmental requirements are of broad clinical and therapeutic interest. Here, we demonstrate that during acute infection, the transcriptional regulator inhibitor of DNA binding 3 (ID3) identifies stem-like T cells that are uniquely adapted to generate precursors of exhausted T (Tpex) cells in response to chronic infection or cancer. Expression of ID3 itself enables Tpex cells to sustain T cell responses in chronic infection or cancer, whereas loss of ID3 results in impaired maintenance of CD8 T cell immunity. Furthermore, we demonstrate that interleukin-1 (IL-1) family members, including IL-36β and IL-18, promote the generation of ID3 + T cells that mediate superior tumor control. Overall, we identify ID3 as a common denominator of stem-like T cells in both acute and chronic infections that is specifically required to sustain T cell responses to chronic stimulation.

15 May 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EGElise Gressier
Elise Gressier
JSJonas Schulte-Schrepping
Jonas Schulte-Schrepping
LPLev Petrov
Lev Petrov
SBSophia Brumhard
Sophia Brumhard
PSPaula Stubbemann
Paula Stubbemann
SBSammy Bedoui
Sammy Bedoui